NASDAQ:NVCN - Neovasc Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.0380 0.00 (0.00 %)
(As of 07/15/2018 03:04 PM ET)
Previous Close$0.0380
Today's Range$0.0380 - $0.0405
52-Week Range$0.03 - $1.89
Volume9.81 million shs
Average Volume28.06 million shs
Market Capitalization$70.69 million
P/E RatioN/A
Dividend YieldN/A
Beta1.14
Neovasc logoNeovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.

Receive NVCN News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NVCN
CUSIPN/A
Phone604-270-4344

Debt

Debt-to-Equity Ratio-0.73
Current Ratio0.92
Quick Ratio0.90

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.39 million
Price / Sales13.11
Cash FlowN/A
Price / CashN/A
Book Value($0.46) per share
Price / Book-0.08

Profitability

EPS (Most Recent Fiscal Year)($0.37)
Net Income$-22,900,000.00
Net Margins-1,687.90%
Return on EquityN/A
Return on Assets-52.15%

Miscellaneous

Employees147
Outstanding Shares1,860,190,000
Market Cap$70.69

The Truth About Cryptocurrencies

Neovasc (NASDAQ:NVCN) Frequently Asked Questions

What is Neovasc's stock symbol?

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

How were Neovasc's earnings last quarter?

Neovasc Inc (NASDAQ:NVCN) announced its quarterly earnings data on Thursday, May, 10th. The medical equipment provider reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.01) by $0.10. The medical equipment provider earned $0.34 million during the quarter, compared to analyst estimates of $1.16 million. View Neovasc's Earnings History.

When is Neovasc's next earnings date?

Neovasc is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Neovasc.

What price target have analysts set for NVCN?

2 Wall Street analysts have issued 1 year price targets for Neovasc's shares. Their forecasts range from $0.50 to $2.00. On average, they anticipate Neovasc's share price to reach $1.25 in the next twelve months. This suggests a possible upside of 3,189.5% from the stock's current price. View Analyst Ratings for Neovasc.

What is the consensus analysts' recommendation for Neovasc?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Are investors shorting Neovasc?

Neovasc saw a decline in short interest during the month of June. As of June 29th, there was short interest totalling 88,218,926 shares, a decline of 6.1% from the June 15th total of 93,903,575 shares. Based on an average trading volume of 41,416,474 shares, the days-to-cover ratio is presently 2.1 days. View Neovasc's Current Options Chain.

Who are some of Neovasc's key competitors?

Who are Neovasc's key executives?

Neovasc's management team includes the folowing people:
  • Mr. Fredericus A. Colen, Pres & CEO (Age 65)
  • Mr. Christopher Clark BA (Honours), PgD, CA, CFO & Corp. Sec. (Age 46)
  • Ms. Vicki Bebeau, VP of Clinical & Regulatory Affairs (Age 67)
  • Mr. Randy Lane, VP of New Concept Devel. & Intellectual Property (Age 45)
  • Mr. Alexei J. Marko, Advisor & Director (Age 49)

Has Neovasc been receiving favorable news coverage?

News headlines about NVCN stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Neovasc earned a news impact score of 0.13 on Accern's scale. They also gave media coverage about the medical equipment provider an impact score of 46.76 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Neovasc?

Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neovasc's stock price today?

One share of NVCN stock can currently be purchased for approximately $0.0380.

How big of a company is Neovasc?

Neovasc has a market capitalization of $70.69 million and generates $5.39 million in revenue each year. The medical equipment provider earns $-22,900,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Neovasc employs 147 workers across the globe.

How can I contact Neovasc?

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, Richmond A1, V6V 2J7. The medical equipment provider can be reached via phone at 604-270-4344 or via email at [email protected]


MarketBeat Community Rating for Neovasc (NASDAQ NVCN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  212 (Vote Outperform)
Underperform Votes:  177 (Vote Underperform)
Total Votes:  389
MarketBeat's community ratings are surveys of what our community members think about Neovasc and other stocks. Vote "Outperform" if you believe NVCN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.